ARHGEF7 antibody is a research tool targeting the ARHGEF7 protein, also known as β-Pix (Rho guanine nucleotide exchange factor 7). ARHGEF7 belongs to the Rho GEF family, which regulates cytoskeletal dynamics, cell adhesion, and migration by activating Rho GTPases like Rac1 and Cdc42. The protein contains a DH (Dbl homology) domain for GEF activity, a PH (pleckstrin homology) domain for membrane targeting, and SH3 domains facilitating protein-protein interactions. It forms complexes with kinases (e.g., PAK1) and scaffolding proteins (e.g., GIT1), influencing signaling pathways such as MAPK and PI3K/AKT.
ARHGEF7 antibodies are widely used in immunoblotting (Western blot), immunofluorescence, and immunoprecipitation to study its expression, localization, and interactions. These antibodies help elucidate ARHGEF7's roles in neuronal development (synaptic plasticity, axon guidance), immune cell trafficking, and cancer progression (metastasis, invasion). Dysregulation of ARHGEF7 is linked to neurodevelopmental disorders, cardiovascular diseases, and malignancies like glioblastoma and breast cancer. Commercial ARHGEF7 antibodies are typically raised in rabbits or mice against specific epitopes (e.g., N-terminal or C-terminal regions) and validated for specificity using knockout controls. Researchers rely on these antibodies to explore ARHGEF7's molecular mechanisms and therapeutic potential in pathological contexts.